141 related articles for article (PubMed ID: 10549730)
21. Human pharmacokinetics of low molecular weight heparins.
Cornelli U; Fareed J
Semin Thromb Hemost; 1999; 25 Suppl 3():57-61. PubMed ID: 10549717
[TBL] [Abstract][Full Text] [Related]
22. The present and future of heparin, low molecular weight heparins, pentasaccharide, and hirudin for venous thromboembolism and acute coronary syndromes.
Haas S
Semin Vasc Med; 2003 May; 3(2):139-46. PubMed ID: 15199477
[TBL] [Abstract][Full Text] [Related]
23. Experimental and clinical validation of the prophylactic antithrombotic effects of a low molecular weight heparin (enoxaparin).
Fareed J; Walenga JM; Hoppensteadt D; Borris LC; Lassen MR
Semin Thromb Hemost; 1991; 17 Suppl 3():319-28. PubMed ID: 1661440
[TBL] [Abstract][Full Text] [Related]
24. A review of the two major regulatory pathways for non-proprietary low-molecular-weight heparins.
Ofosu FA
Thromb Haemost; 2012 Feb; 107(2):201-14. PubMed ID: 22234312
[TBL] [Abstract][Full Text] [Related]
25. [State of the art: low-molecular-weight heparin and beyond].
Cimminiello C; Casali G; Vitali L
Minerva Cardioangiol; 2000 Dec; 48(12 Suppl 1):61-5. PubMed ID: 11253343
[TBL] [Abstract][Full Text] [Related]
26. Low-molecular-weight heparins and angiogenesis.
Norrby K
APMIS; 2006 Feb; 114(2):79-102. PubMed ID: 16519745
[TBL] [Abstract][Full Text] [Related]
27. Low molecular weight heparins: background and pharmacology.
Morris TA
Semin Respir Crit Care Med; 2000; 21(6):537-46. PubMed ID: 16088762
[TBL] [Abstract][Full Text] [Related]
28. Are all low molecular weight heparins equivalent in the management of venous thromboembolism?
Fareed J; Jeske W; Fareed D; Clark M; Wahi R; Adiguzel C; Hoppensteadt D
Clin Appl Thromb Hemost; 2008 Oct; 14(4):385-92. PubMed ID: 18815137
[TBL] [Abstract][Full Text] [Related]
29. Low molecular weight heparins in patients with renal insufficiency.
Symes J
CANNT J; 2008; 18(2):55-61. PubMed ID: 18669012
[TBL] [Abstract][Full Text] [Related]
30. Survival of heparins, oral anticoagulants, and aspirin after the year 2010.
Fareed J; Hoppensteadt DA; Fareed D; Demir M; Wahi R; Clarke M; Adiguzel C; Bick R
Semin Thromb Hemost; 2008 Feb; 34(1):58-73. PubMed ID: 18393143
[TBL] [Abstract][Full Text] [Related]
31. Structural and functional characterization of low-molecular-weight heparins: impact on the development of guidelines for generic products.
Adiguzel C; Jeske WP; Hoppensteadt D; Walenga JM; Bansal V; Fareed J
Clin Appl Thromb Hemost; 2009; 15(2):137-44. PubMed ID: 19357102
[TBL] [Abstract][Full Text] [Related]
32. Economics of low-molecular weight heparins.
Rutschmann OT; Matchar DB
Am J Manag Care; 2000 Nov; 6(20 Suppl):S1054-65; quiz 1066-7. PubMed ID: 11484305
[TBL] [Abstract][Full Text] [Related]
33. Opioids and the management of chronic severe pain in the elderly: consensus statement of an International Expert Panel with focus on the six clinically most often used World Health Organization Step III opioids (buprenorphine, fentanyl, hydromorphone, methadone, morphine, oxycodone).
Pergolizzi J; Böger RH; Budd K; Dahan A; Erdine S; Hans G; Kress HG; Langford R; Likar R; Raffa RB; Sacerdote P
Pain Pract; 2008; 8(4):287-313. PubMed ID: 18503626
[TBL] [Abstract][Full Text] [Related]
34. Treatment of deep vein thrombosis using low-molecular-weight heparins.
Groce JB
Am J Manag Care; 2001 Nov; 7(17 Suppl):S510-5; discussion S515-23. PubMed ID: 11732662
[TBL] [Abstract][Full Text] [Related]
35. Biochemical and pharmacologic heterogeneity in low molecular weight heparins. Impact on the therapeutic profile.
Fareed J; Hoppensteadt D; Schultz C; Ma Q; Kujawski MF; Neville B; Messmore H
Curr Pharm Des; 2004; 10(9):983-99. PubMed ID: 15078128
[TBL] [Abstract][Full Text] [Related]
36. Low-molecular-weight heparins and glycoprotein IIb/IIIa antagonists in acute coronary syndromes.
Ferguson J
J Invasive Cardiol; 2004 Mar; 16(3):136-44. PubMed ID: 15152164
[TBL] [Abstract][Full Text] [Related]
37. [Low molecular weight heparins and their non-antithrombotic effects on wound healing].
Toporcer T; Lakyová L; Radonak J
Cas Lek Cesk; 2009; 148(10):481-8. PubMed ID: 20662410
[TBL] [Abstract][Full Text] [Related]
38. Differences of present recommendations and guidelines for generic low-molecular-weight heparins: is there room for harmonization.
Harenberg J
Clin Appl Thromb Hemost; 2011; 17(6):E158-64. PubMed ID: 21406409
[TBL] [Abstract][Full Text] [Related]
39. Low molecular weight heparins: the optimal treatment for venous thromboembolism.
Daskalopoulos ME; Daskalopoulou SS; Liapis CD
Curr Med Res Opin; 2004 Jul; 20(7):1001-5. PubMed ID: 15265244
[TBL] [Abstract][Full Text] [Related]
40. [Low-molecular weight heparin and acute coronary syndrome: theoretical background and its use in clinical practice].
Ottani F; Ferrini D; Di Pasquale G; Galvani M
Ital Heart J Suppl; 2001 Sep; 2(9):958-71. PubMed ID: 11675833
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
